Ovid Therapeutics (OVID) Liabilities and Shareholders Equity (2016 - 2026)

Ovid Therapeutics (OVID) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $232.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 199.6% year-over-year to $232.0 million; the trailing twelve-month figure through Jun 2026 stood at $672.4 million (up 89.99% YoY), and the FY2025 full-year result was $150.9 million, up 63.76% from the prior year.
• Liabilities and Shareholders Equity climbed to $232.0 million in Q2 2026 per OVID's latest filing, from $225.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $232.0 million in Q2 2026 and bottomed at $63.8 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $139.6 million across 5 years, with a median of $139.8 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity tumbled 37.96% in 2025, then jumped 199.6% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $155.3 million in 2022, then dropped by 7.24% to $144.0 million in 2023, then sank by 36.01% to $92.2 million in 2024, then soared by 63.76% to $150.9 million in 2025, then surged by 53.69% to $232.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $232.0 million, $225.6 million, and $150.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.